Clinical Trials Directory

Trials / Completed

CompletedNCT02384382

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
23 (actual)
Sponsor
Pfizer · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who are receiving enzalutamide for castration-resistant prostate cancer.

Conditions

Interventions

TypeNameDescription
DRUGEnzalutamide

Timeline

Start date
2015-11-30
Primary completion
2019-05-03
Completion
2019-05-03
First posted
2015-03-10
Last updated
2020-05-05
Results posted
2020-05-05

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02384382. Inclusion in this directory is not an endorsement.